speb/financial-data huggingface dataset:
DME.V cash_flow (quarterly, 2025-09-30) — Change In Account Payable: 41838.00
DME.V cash_flow (annual, 2025-09-30) — Change In Payable: -2381.00
DME.V cash_flow (quarterly, 2025-09-30) — Change In Payable: 41838.00
DME.V cash_flow (annual, 2025-09-30) — Change In Payables And Accrued Expense: -2381.00
DME.V cash_flow (quarterly, 2025-09-30) — Change In Payables And Accrued Expense: 41838.00
DME.V cash_flow (annual, 2025-09-30) — Change In Prepaid Assets: 76591.00
DME.V cash_flow (quarterly, 2025-09-30) — Change In Prepaid Assets: 70170.00
DME.V cash_flow (annual, 2025-09-30) — Change In Receivables: 210616.00
DME.V cash_flow (quarterly, 2025-09-30) — Change In Receivables: -28188.00
DME.V cash_flow (annual, 2025-09-30) — Change In Working Capital: 284826.00
DME.V cash_flow (quarterly, 2025-09-30) — Change In Working Capital: 83820.00
DME.V cash_flow (annual, 2025-09-30) — Changes In Cash: -930728.00
DME.V cash_flow (quarterly, 2025-09-30) — Changes In Cash: -226998.00
DME.V balance_sheet (annual, 2025-09-30) — Common Stock: 81562776.00
DME.V balance_sheet (quarterly, 2025-09-30) — Common Stock: 81562776.00
DME.V balance_sheet (annual, 2025-09-30) — Common Stock Equity: 47367164.00
DME.V balance_sheet (quarterly, 2025-09-30) — Common Stock Equity: 47367164.00
DME.V cash_flow (annual, 2025-09-30) — Common Stock Issuance: 887397.00
DME.V cash_flow (quarterly, 2025-09-30) — Common Stock Issuance: -16143.00
DME.V income_statement (annual, 2025-09-30) — Cost Of Revenue: 526484.00
DME.V income_statement (quarterly, 2025-09-30) — Cost Of Revenue: 43513.00
DME.V balance_sheet (annual, 2025-09-30) — Current Assets: 634135.00
DME.V balance_sheet (quarterly, 2025-09-30) — Current Assets: 634135.00
DME.V balance_sheet (annual, 2025-09-30) — Current Liabilities: 433266.00
DME.V balance_sheet (quarterly, 2025-09-30) — Current Liabilities: 433266.00
DME.V cash_flow (annual, 2025-09-30) — Depletion: 7322.00
DME.V cash_flow (quarterly, 2025-09-30) — Depletion: 3535.00
DME.V cash_flow (annual, 2025-09-30) — Depreciation: 114589.00
DME.V cash_flow (quarterly, 2025-09-30) — Depreciation: 78106.00
DME.V cash_flow (annual, 2025-09-30) — Depreciation Amortization Depletion: 121911.00
DME.V cash_flow (quarterly, 2025-09-30) — Depreciation Amortization Depletion: 81641.00
DME.V income_statement (annual, 2025-09-30) — Depreciation Amortization Depletion Income Statement: 114589.00
DME.V income_statement (quarterly, 2025-09-30) — Depreciation Amortization Depletion Income Statement: 78106.00
DME.V cash_flow (annual, 2025-09-30) — Depreciation And Amortization: 114589.00
DME.V cash_flow (quarterly, 2025-09-30) — Depreciation And Amortization: 78106.00
DME.V income_statement (annual, 2025-09-30) — Depreciation And Amortization In Income Statement: 114589.00
DME.V income_statement (quarterly, 2025-09-30) — Depreciation And Amortization In Income Statement: 78106.00
DME.V income_statement (annual, 2025-09-30) — Depreciation Income Statement: 114589.00
DME.V income_statement (quarterly, 2025-09-30) — Depreciation Income Statement: 78106.00
DME.V income_statement (annual, 2025-09-30) — Diluted Average Shares: 92363506.00
DME.V income_statement (annual, 2025-09-30) — Diluted EPS: -0.02
DME.V income_statement (annual, 2025-09-30) — Diluted NI Availto Com Stockholders: -2299464.00
DME.V income_statement (quarterly, 2025-09-30) — Diluted NI Availto Com Stockholders: -545288.00
DME.V balance_sheet (annual, 2025-09-30) — Dueto Related Parties Current: 0.00
DME.V balance_sheet (quarterly, 2025-09-30) — Dueto Related Parties Current: 0.00
DME.V income_statement (annual, 2025-09-30) — EBIT: -2739764.00
DME.V income_statement (quarterly, 2025-09-30) — EBIT: -726061.00
DME.V income_statement (annual, 2025-09-30) — EBITDA: -2617853.00
DME.V income_statement (quarterly, 2025-09-30) — EBITDA: -644420.00
DME.V cash_flow (annual, 2025-09-30) — Effect Of Exchange Rate Changes: 19810.00
DME.V cash_flow (quarterly, 2025-09-30) — Effect Of Exchange Rate Changes: 123130.00
DME.V cash_flow (annual, 2025-09-30) — End Cash Position: 272542.00
DME.V cash_flow (quarterly, 2025-09-30) — End Cash Position: 272542.00
DME.V cash_flow (annual, 2025-09-30) — Financing Cash Flow: 887397.00
DME.V cash_flow (quarterly, 2025-09-30) — Financing Cash Flow: -16143.00
DME.V cash_flow (annual, 2025-09-30) — Free Cash Flow: -2586307.00
DME.V cash_flow (quarterly, 2025-09-30) — Free Cash Flow: -523151.00
DME.V cash_flow (annual, 2025-09-30) — Gain Loss On Sale Of PPE: 0.00
DME.V cash_flow (quarterly, 2025-09-30) — Gain Loss On Sale Of PPE: 0.00
DME.V income_statement (annual, 2025-09-30) — Gain On Sale Of Ppe: -2490.00
DME.V income_statement (quarterly, 2025-09-30) — Gain On Sale Of Ppe: -2490.00
DME.V income_statement (annual, 2025-09-30) — Gain On Sale Of Security: -1441.00
DME.V income_statement (quarterly, 2025-09-30) — Gain On Sale Of Security: 723.00
DME.V balance_sheet (annual, 2025-09-30) — Gains Losses Not Affecting Retained Earnings: 3162039.00
DME.V balance_sheet (quarterly, 2025-09-30) — Gains Losses Not Affecting Retained Earnings: 3162039.00
DME.V income_statement (annual, 2025-09-30) — General And Administrative Expense: 1451319.00
DME.V income_statement (quarterly, 2025-09-30) — General And Administrative Expense: 414586.00
DME.V balance_sheet (annual, 2025-09-30) — Gross PPE: 59617689.00
DME.V balance_sheet (quarterly, 2025-09-30) — Gross PPE: 59617689.00
DME.V income_statement (annual, 2025-09-30) — Gross Profit: -149256.00
DME.V income_statement (quarterly, 2025-09-30) — Gross Profit: -28253.00
DME.V balance_sheet (annual, 2025-09-30) — Held To Maturity Securities: 196225.00
DME.V balance_sheet (quarterly, 2025-09-30) — Held To Maturity Securities: 196225.00
DME.V income_statement (annual, 2025-09-30) — Insurance And Claims: 256486.00
DME.V income_statement (quarterly, 2025-09-30) — Insurance And Claims: 107620.00
DME.V income_statement (annual, 2025-09-30) — Interest Income: 295708.00
DME.V income_statement (quarterly, 2025-09-30) — Interest Income: 34017.00
DME.V income_statement (annual, 2025-09-30) — Interest Income Non Operating: 295708.00
DME.V income_statement (quarterly, 2025-09-30) — Interest Income Non Operating: 34017.00
DME.V balance_sheet (annual, 2025-09-30) — Invested Capital: 47367164.00
DME.V balance_sheet (quarterly, 2025-09-30) — Invested Capital: 47367164.00
DME.V cash_flow (annual, 2025-09-30) — Investing Cash Flow: 224932.00
DME.V cash_flow (quarterly, 2025-09-30) — Investing Cash Flow: 257077.00
DME.V balance_sheet (annual, 2025-09-30) — Investmentin Financial Assets: 196225.00
DME.V balance_sheet (quarterly, 2025-09-30) — Investmentin Financial Assets: 196225.00
DME.V balance_sheet (annual, 2025-09-30) — Investments And Advances: 196225.00
DME.V balance_sheet (quarterly, 2025-09-30) — Investments And Advances: 196225.00
DME.V cash_flow (annual, 2025-09-30) — Issuance Of Capital Stock: 887397.00
DME.V cash_flow (quarterly, 2025-09-30) — Issuance Of Capital Stock: -16143.00
DME.V balance_sheet (annual, 2025-09-30) — Land And Improvements: 279699.00
DME.V balance_sheet (quarterly, 2025-09-30) — Land And Improvements: 279699.00
DME.V balance_sheet (annual, 2025-09-30) — Long Term Provisions: 2765567.00
DME.V balance_sheet (quarterly, 2025-09-30) — Long Term Provisions: 2765567.00
DME.V cash_flow (annual, 2025-09-30) — Net Common Stock Issuance: 887397.00
DME.V cash_flow (quarterly, 2025-09-30) — Net Common Stock Issuance: -16143.00
DME.V cash_flow (annual, 2025-09-30) — Net Foreign Currency Exchange Gain Loss: -17026.00
DME.V cash_flow (quarterly, 2025-09-30) — Net Foreign Currency Exchange Gain Loss: -19190.00
DME.V income_statement (annual, 2025-09-30) — Net Income: -2299464.00
DME.V income_statement (quarterly, 2025-09-30) — Net Income: -545288.00
DME.V income_statement (annual, 2025-09-30) — Net Income Common Stockholders: -2299464.00
DME.V income_statement (quarterly, 2025-09-30) — Net Income Common Stockholders: -545288.00
DME.V income_statement (annual, 2025-09-30) — Net Income Continuous Operations: -2299464.00
DME.V income_statement (quarterly, 2025-09-30) — Net Income Continuous Operations: -545288.00
DME.V income_statement (annual, 2025-09-30) — Net Income From Continuing And Discontinued Operation: -2299464.00
DME.V income_statement (quarterly, 2025-09-30) — Net Income From Continuing And Discontinued Operation: -545288.00
DME.V income_statement (annual, 2025-09-30) — Net Income From Continuing Operation Net Minority Interest: -2299464.00
DME.V income_statement (quarterly, 2025-09-30) — Net Income From Continuing Operation Net Minority Interest: -545288.00
DME.V cash_flow (annual, 2025-09-30) — Net Income From Continuing Operations: -2299464.00
DME.V cash_flow (quarterly, 2025-09-30) — Net Income From Continuing Operations: -545288.00
DME.V income_statement (annual, 2025-09-30) — Net Income Including Noncontrolling Interests: -2299464.00
DME.V income_statement (quarterly, 2025-09-30) — Net Income Including Noncontrolling Interests: -545288.00
DME.V income_statement (annual, 2025-09-30) — Net Interest Income: 295708.00
DME.V income_statement (quarterly, 2025-09-30) — Net Interest Income: 34017.00
DME.V income_statement (annual, 2025-09-30) — Net Non Operating Interest Income Expense: 295708.00
DME.V income_statement (quarterly, 2025-09-30) — Net Non Operating Interest Income Expense: 34017.00
DME.V cash_flow (annual, 2025-09-30) — Net Other Investing Changes: 768182.00
DME.V cash_flow (quarterly, 2025-09-30) — Net Other Investing Changes: 312296.00
DME.V balance_sheet (annual, 2025-09-30) — Net PPE: 48436940.00
DME.V balance_sheet (quarterly, 2025-09-30) — Net PPE: 48436940.00
DME.V balance_sheet (annual, 2025-09-30) — Net Tangible Assets: 47367164.00
DME.V balance_sheet (quarterly, 2025-09-30) — Net Tangible Assets: 47367164.00
DME.V balance_sheet (annual, 2025-09-30) — Non Current Accounts Receivable: 483396.00
DME.V balance_sheet (quarterly, 2025-09-30) — Non Current Accounts Receivable: 483396.00
DME.V balance_sheet (annual, 2025-09-30) — Non Current Note Receivables: 0.00
DME.V balance_sheet (quarterly, 2025-09-30) — Non Current Note Receivables: 0.00
DME.V income_statement (annual, 2025-09-30) — Normalized EBITDA: -2762445.00
DME.V income_statement (quarterly, 2025-09-30) — Normalized EBITDA: -791176.00
DME.V income_statement (annual, 2025-09-30) — Normalized Income: -2444056.00
DME.V income_statement (quarterly, 2025-09-30) — Normalized Income: -692044.00
DME.V cash_flow (annual, 2025-09-30) — Operating Cash Flow: -2043057.00
DME.V cash_flow (quarterly, 2025-09-30) — Operating Cash Flow: -467932.00
DME.V cash_flow (annual, 2025-09-30) — Operating Gains Losses: -17026.00
DME.V cash_flow (quarterly, 2025-09-30) — Operating Gains Losses: -19190.00
DME.V income_statement (annual, 2025-09-30) — Operating Income: -2739764.00
DME.V income_statement (quarterly, 2025-09-30) — Operating Income: -726061.00
DME.V income_statement (annual, 2025-09-30) — Operating Revenue: 377228.00
DME.V income_statement (quarterly, 2025-09-30) — Operating Revenue: 15260.00
DME.V balance_sheet (annual, 2025-09-30) — Ordinary Shares Number: 94184109.00
DME.V balance_sheet (quarterly, 2025-09-30) — Ordinary Shares Number: 94184109.00
DME.V balance_sheet (annual, 2025-09-30) — Other Equity Adjustments: 3162039.00
DME.V balance_sheet (quarterly, 2025-09-30) — Other Equity Adjustments: 3162039.00
DME.V balance_sheet (annual, 2025-09-30) — Other Equity Interest: 17582267.00
DME.V balance_sheet (quarterly, 2025-09-30) — Other Equity Interest: 17582267.00
DME.V income_statement (annual, 2025-09-30) — Other Gand A: 1129046.00
DME.V income_statement (quarterly, 2025-09-30) — Other Gand A: 290659.00
DME.V income_statement (annual, 2025-09-30) — Other Income Expense: 144592.00
DME.V income_statement (quarterly, 2025-09-30) — Other Income Expense: 146756.00
DME.V cash_flow (annual, 2025-09-30) — Other Non Cash Items: -133304.00
DME.V cash_flow (quarterly, 2025-09-30) — Other Non Cash Items: -68915.00
DME.V balance_sheet (annual, 2025-09-30) — Other Non Current Assets: 815301.00
DME.V balance_sheet (quarterly, 2025-09-30) — Other Non Current Assets: 815301.00
DME.V income_statement (annual, 2025-09-30) — Other Operating Expenses: 443970.00
DME.V income_statement (quarterly, 2025-09-30) — Other Operating Expenses: 124258.00
DME.V balance_sheet (annual, 2025-09-30) — Other Properties: 59337990.00
DME.V balance_sheet (quarterly, 2025-09-30) — Other Properties: 59337990.00
DME.V balance_sheet (annual, 2025-09-30) — Other Receivables: 273273.00
DME.V balance_sheet (quarterly, 2025-09-30) — Other Receivables: 273273.00
DME.V balance_sheet (annual, 2025-09-30) — Payables: 433266.00
DME.V balance_sheet (quarterly, 2025-09-30) — Payables: 433266.00
DME.V balance_sheet (annual, 2025-09-30) — Payables And Accrued Expenses: 433266.00
DME.V balance_sheet (quarterly, 2025-09-30) — Payables And Accrued Expenses: 433266.00
DME.V balance_sheet (annual, 2025-09-30) — Prepaid Assets: 10452.00
DME.V balance_sheet (quarterly, 2025-09-30) — Prepaid Assets: 10452.00
DME.V income_statement (annual, 2025-09-30) — Pretax Income: -2299464.00
DME.V income_statement (quarterly, 2025-09-30) — Pretax Income: -545288.00
DME.V cash_flow (annual, 2025-09-30) — Provisionand Write Offof Assets: 0.00
DME.V balance_sheet (annual, 2025-09-30) — Receivables: 351141.00
DME.V balance_sheet (quarterly, 2025-09-30) — Receivables: 351141.00
DME.V income_statement (annual, 2025-09-30) — Reconciled Cost Of Revenue: 519162.00
DME.V income_statement (quarterly, 2025-09-30) — Reconciled Cost Of Revenue: 39978.00
DME.V income_statement (annual, 2025-09-30) — Reconciled Depreciation: 121911.00
DME.V income_statement (quarterly, 2025-09-30) — Reconciled Depreciation: 81641.00
DME.V income_statement (annual, 2025-09-30) — Restructuring And Mergern Acquisition: -148523.00
DME.V balance_sheet (annual, 2025-09-30) — Retained Earnings: -54939918.00
DME.V balance_sheet (quarterly, 2025-09-30) — Retained Earnings: -54939918.00
DME.V income_statement (annual, 2025-09-30) — Salaries And Wages: 65787.00
DME.V income_statement (quarterly, 2025-09-30) — Salaries And Wages: 16307.00
DME.V income_statement (annual, 2025-09-30) — Selling And Marketing Expense: 155184.00
DME.V income_statement (quarterly, 2025-09-30) — Selling And Marketing Expense: 78557.00
DME.V income_statement (annual, 2025-09-30) — Selling General And Administration: 1606503.00
DME.V income_statement (quarterly, 2025-09-30) — Selling General And Administration: 493143.00
DME.V balance_sheet (annual, 2025-09-30) — Share Issued: 94184109.00
DME.V balance_sheet (quarterly, 2025-09-30) — Share Issued: 94184109.00
DME.V income_statement (annual, 2025-09-30) — Special Income Charges: 146033.00
DME.V income_statement (quarterly, 2025-09-30) — Special Income Charges: 146033.00
DME.V cash_flow (annual, 2025-09-30) — Stock Based Compensation: 0.00
DME.V cash_flow (quarterly, 2025-09-30) — Stock Based Compensation: 0.00
DME.V balance_sheet (annual, 2025-09-30) — Stockholders Equity: 47367164.00
DME.V balance_sheet (quarterly, 2025-09-30) — Stockholders Equity: 47367164.00
DME.V balance_sheet (annual, 2025-09-30) — Tangible Book Value: 47367164.00
DME.V balance_sheet (quarterly, 2025-09-30) — Tangible Book Value: 47367164.00
DME.V income_statement (annual, 2025-09-30) — Tax Effect Of Unusual Items: 0.00
DME.V income_statement (quarterly, 2025-09-30) — Tax Effect Of Unusual Items: 0.00
DME.V income_statement (annual, 2025-09-30) — Tax Rate For Calcs: 0.00
DME.V income_statement (quarterly, 2025-09-30) — Tax Rate For Calcs: 0.00
DME.V balance_sheet (annual, 2025-09-30) — Total Assets: 50565997.00
DME.V balance_sheet (quarterly, 2025-09-30) — Total Assets: 50565997.00
DME.V balance_sheet (annual, 2025-09-30) — Total Capitalization: 47367164.00
DME.V balance_sheet (quarterly, 2025-09-30) — Total Capitalization: 47367164.00
DME.V balance_sheet (annual, 2025-09-30) — Total Equity Gross Minority Interest: 47367164.00
DME.V balance_sheet (quarterly, 2025-09-30) — Total Equity Gross Minority Interest: 47367164.00
DME.V income_statement (annual, 2025-09-30) — Total Expenses: 3116992.00
DME.V income_statement (quarterly, 2025-09-30) — Total Expenses: 741321.00
DME.V balance_sheet (annual, 2025-09-30) — Total Liabilities Net Minority Interest: 3198833.00
DME.V balance_sheet (quarterly, 2025-09-30) — Total Liabilities Net Minority Interest: 3198833.00
DME.V balance_sheet (annual, 2025-09-30) — Total Non Current Assets: 49931862.00
DME.V balance_sheet (quarterly, 2025-09-30) — Total Non Current Assets: 49931862.00
DME.V balance_sheet (annual, 2025-09-30) — Total Non Current Liabilities Net Minority Interest: 2765567.00
DME.V balance_sheet (quarterly, 2025-09-30) — Total Non Current Liabilities Net Minority Interest: 2765567.00
DME.V income_statement (annual, 2025-09-30) — Total Unusual Items: 144592.00
DME.V income_statement (quarterly, 2025-09-30) — Total Unusual Items: 146756.00
DME.V income_statement (annual, 2025-09-30) — Total Unusual Items Excluding Goodwill: 144592.00
DME.V income_statement (quarterly, 2025-09-30) — Total Unusual Items Excluding Goodwill: 146756.00
DME.V balance_sheet (annual, 2025-09-30) — Working Capital: 200869.00
DME.V balance_sheet (quarterly, 2025-09-30) — Working Capital: 200869.00
DME.V income_statement (annual, 2025-09-30) — Write Off: 0.00
DME.V income_statement (quarterly, 2025-12-31) — +Operating Expense: 311314.00
DME.V income_statement (quarterly, 2025-12-31) — +Total Revenue: 62054.00
DME.V balance_sheet (quarterly, 2025-12-31) — Accounts Payable: 308961.00
DME.V balance_sheet (quarterly, 2025-12-31) — Accounts Receivable: 187773.00
DME.V balance_sheet (quarterly, 2025-12-31) — Accumulated Depreciation: -11351736.00
DME.V income_statement (quarterly, 2025-12-31) — Basic Average Shares: 94589401.00
DME.V income_statement (quarterly, 2025-12-31) — Basic EPS: 0.00
DME.V cash_flow (quarterly, 2025-12-31) — Beginning Cash Position: 272542.00
DME.V cash_flow (quarterly, 2025-12-31) — Capital Expenditure: -52273.00
DME.V cash_flow (quarterly, 2025-12-31) — Capital Expenditure Reported: -52273.00
DME.V balance_sheet (quarterly, 2025-12-31) — Capital Stock: 81736813.00
DME.V balance_sheet (quarterly, 2025-12-31) — Cash And Cash Equivalents: 54070.00
DME.V balance_sheet (quarterly, 2025-12-31) — Cash Cash Equivalents And Short Term Investments: 54070.00
DME.V cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Financing Activities: 171881.00
DME.V cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Investing Activities: -6125.00
DME.V cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Operating Activities: -331770.00
DME.V cash_flow (quarterly, 2025-12-31) — Change In Account Payable: -124305.00
DME.V cash_flow (quarterly, 2025-12-31) — Change In Payable: -124305.00
DME.V cash_flow (quarterly, 2025-12-31) — Change In Payables And Accrued Expense: -124305.00
DME.V cash_flow (quarterly, 2025-12-31) — Change In Prepaid Assets: -28600.00
DME.V cash_flow (quarterly, 2025-12-31) — Change In Receivables: -112963.00
DME.V cash_flow (quarterly, 2025-12-31) — Change In Working Capital: -265868.00
DME.V cash_flow (quarterly, 2025-12-31) — Changes In Cash: -166014.00
DME.V balance_sheet (quarterly, 2025-12-31) — Common Stock: 81736813.00
DME.V balance_sheet (quarterly, 2025-12-31) — Common Stock Equity: 46665176.00
DME.V income_statement (quarterly, 2025-12-31) — Cost Of Revenue: 52294.00
DME.V balance_sheet (quarterly, 2025-12-31) — Current Assets: 554601.00
DME.V balance_sheet (quarterly, 2025-12-31) — Current Liabilities: 308961.00
DME.V cash_flow (quarterly, 2025-12-31) — Depletion: 942.00
DME.V cash_flow (quarterly, 2025-12-31) — Depreciation: 48457.00
DME.V cash_flow (quarterly, 2025-12-31) — Depreciation Amortization Depletion: 49399.00
DME.V income_statement (quarterly, 2025-12-31) — Depreciation Amortization Depletion Income Statement: 48457.00
DME.V cash_flow (quarterly, 2025-12-31) — Depreciation And Amortization: 48457.00
DME.V income_statement (quarterly, 2025-12-31) — Depreciation And Amortization In Income Statement: 48457.00
DME.V income_statement (quarterly, 2025-12-31) — Depreciation Income Statement: 48457.00
DME.V income_statement (quarterly, 2025-12-31) — Diluted Average Shares: 94589401.00
DME.V income_statement (quarterly, 2025-12-31) — Diluted EPS: 0.00
DME.V income_statement (quarterly, 2025-12-31) — Diluted NI Availto Com Stockholders: -154788.00
DME.V income_statement (quarterly, 2025-12-31) — EBIT: -301554.00
DME.V income_statement (quarterly, 2025-12-31) — EBITDA: -252155.00
DME.V cash_flow (quarterly, 2025-12-31) — Effect Of Exchange Rate Changes: -52458.00
DME.V cash_flow (quarterly, 2025-12-31) — End Cash Position: 54070.00
DME.V cash_flow (quarterly, 2025-12-31) — Financing Cash Flow: 171881.00
DME.V cash_flow (quarterly, 2025-12-31) — Free Cash Flow: -384043.00
DME.V income_statement (quarterly, 2025-12-31) — Gain On Sale Of Security: -1573.00
DME.V balance_sheet (quarterly, 2025-12-31) — Gains Losses Not Affecting Retained Earnings: 2442958.00
DME.V income_statement (quarterly, 2025-12-31) — General And Administrative Expense: 149420.00
DME.V balance_sheet (quarterly, 2025-12-31) — Gross PPE: 58973212.00
DME.V income_statement (quarterly, 2025-12-31) — Gross Profit: 9760.00
DME.V balance_sheet (quarterly, 2025-12-31) — Held To Maturity Securities: 193272.00
DME.V income_statement (quarterly, 2025-12-31) — Insurance And Claims: 17177.00
DME.V income_statement (quarterly, 2025-12-31) — Interest Income: 20860.00
DME.V income_statement (quarterly, 2025-12-31) — Interest Income Non Operating: 20860.00
DME.V balance_sheet (quarterly, 2025-12-31) — Invested Capital: 46665176.00
DME.V cash_flow (quarterly, 2025-12-31) — Investing Cash Flow: -6125.00
DME.V balance_sheet (quarterly, 2025-12-31) — Investmentin Financial Assets: 193272.00
DME.V balance_sheet (quarterly, 2025-12-31) — Investments And Advances: 193272.00
DME.V balance_sheet (quarterly, 2025-12-31) — Land And Improvements: 275488.00
DME.V balance_sheet (quarterly, 2025-12-31) — Long Term Provisions: 2622977.00
DME.V cash_flow (quarterly, 2025-12-31) — Net Foreign Currency Exchange Gain Loss: 27382.00
DME.V income_statement (quarterly, 2025-12-31) — Net Income: -154788.00
DME.V income_statement (quarterly, 2025-12-31) — Net Income Common Stockholders: -154788.00
DME.V income_statement (quarterly, 2025-12-31) — Net Income Continuous Operations: -154788.00
DME.V income_statement (quarterly, 2025-12-31) — Net Income From Continuing And Discontinued Operation: -154788.00
DME.V income_statement (quarterly, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: -154788.00
DME.V cash_flow (quarterly, 2025-12-31) — Net Income From Continuing Operations: -154788.00
DME.V income_statement (quarterly, 2025-12-31) — Net Income Including Noncontrolling Interests: -154788.00
DME.V income_statement (quarterly, 2025-12-31) — Net Interest Income: 20860.00
DME.V income_statement (quarterly, 2025-12-31) — Net Non Operating Interest Income Expense: 20860.00
DME.V cash_flow (quarterly, 2025-12-31) — Net Other Investing Changes: 46148.00
DME.V balance_sheet (quarterly, 2025-12-31) — Net PPE: 47621476.00
DME.V balance_sheet (quarterly, 2025-12-31) — Net Tangible Assets: 46665176.00
DME.V balance_sheet (quarterly, 2025-12-31) — Non Current Accounts Receivable: 424737.00
DME.V income_statement (quarterly, 2025-12-31) — Normalized EBITDA: -378061.00
DME.V income_statement (quarterly, 2025-12-31) — Normalized Income: -280694.00
DME.V cash_flow (quarterly, 2025-12-31) — Operating Cash Flow: -331770.00
DME.V cash_flow (quarterly, 2025-12-31) — Operating Gains Losses: 27382.00
DME.V income_statement (quarterly, 2025-12-31) — Operating Income: -301554.00
DME.V income_statement (quarterly, 2025-12-31) — Operating Revenue: 62054.00
DME.V balance_sheet (quarterly, 2025-12-31) — Ordinary Shares Number: 94675197.00
DME.V balance_sheet (quarterly, 2025-12-31) — Other Equity Adjustments: 2442958.00
DME.V balance_sheet (quarterly, 2025-12-31) — Other Equity Interest: 17580111.00
DME.V income_statement (quarterly, 2025-12-31) — Other Gand A: 115916.00
DME.V income_statement (quarterly, 2025-12-31) — Other Income Expense: 125906.00
DME.V cash_flow (quarterly, 2025-12-31) — Other Non Cash Items: 12105.00
DME.V balance_sheet (quarterly, 2025-12-31) — Other Non Current Assets: 803028.00
DME.V income_statement (quarterly, 2025-12-31) — Other Operating Expenses: 89942.00
DME.V balance_sheet (quarterly, 2025-12-31) — Other Properties: 58697724.00
DME.V balance_sheet (quarterly, 2025-12-31) — Other Receivables: 273727.00
DME.V balance_sheet (quarterly, 2025-12-31) — Payables: 308961.00
DME.V balance_sheet (quarterly, 2025-12-31) — Payables And Accrued Expenses: 308961.00
DME.V balance_sheet (quarterly, 2025-12-31) — Prepaid Assets: 39031.00
DME.V income_statement (quarterly, 2025-12-31) — Pretax Income: -154788.00
DME.V cash_flow (quarterly, 2025-12-31) — Proceeds From Stock Option Exercised: 171881.00
DME.V balance_sheet (quarterly, 2025-12-31) — Receivables: 461500.00
DME.V income_statement (quarterly, 2025-12-31) — Reconciled Cost Of Revenue: 51352.00
DME.V income_statement (quarterly, 2025-12-31) — Reconciled Depreciation: 49399.00
DME.V income_statement (quarterly, 2025-12-31) — Restructuring And Mergern Acquisition: -127479.00
DME.V balance_sheet (quarterly, 2025-12-31) — Retained Earnings: -55094706.00
DME.V income_statement (quarterly, 2025-12-31) — Salaries And Wages: 16327.00
DME.V income_statement (quarterly, 2025-12-31) — Selling And Marketing Expense: 11247.00
DME.V income_statement (quarterly, 2025-12-31) — Selling General And Administration: 160667.00
DME.V balance_sheet (quarterly, 2025-12-31) — Share Issued: 94675197.00
DME.V income_statement (quarterly, 2025-12-31) — Special Income Charges: 127479.00
DME.V balance_sheet (quarterly, 2025-12-31) — Stockholders Equity: 46665176.00
DME.V balance_sheet (quarterly, 2025-12-31) — Tangible Book Value: 46665176.00
DME.V income_statement (quarterly, 2025-12-31) — Tax Effect Of Unusual Items: 0.00
DME.V income_statement (quarterly, 2025-12-31) — Tax Rate For Calcs: 0.00
DME.V balance_sheet (quarterly, 2025-12-31) — Total Assets: 49597114.00
DME.V balance_sheet (quarterly, 2025-12-31) — Total Capitalization: 46665176.00
DME.V balance_sheet (quarterly, 2025-12-31) — Total Equity Gross Minority Interest: 46665176.00
DME.V income_statement (quarterly, 2025-12-31) — Total Expenses: 363608.00
DME.V balance_sheet (quarterly, 2025-12-31) — Total Liabilities Net Minority Interest: 2931938.00
DME.V balance_sheet (quarterly, 2025-12-31) — Total Non Current Assets: 49042513.00
DME.V balance_sheet (quarterly, 2025-12-31) — Total Non Current Liabilities Net Minority Interest: 2622977.00
DME.V income_statement (quarterly, 2025-12-31) — Total Unusual Items: 125906.00
DME.V income_statement (quarterly, 2025-12-31) — Total Unusual Items Excluding Goodwill: 125906.00
DME.V balance_sheet (quarterly, 2025-12-31) — Working Capital: 245640.00
DME.V income_statement (quarterly, 2026-03-31) — +Operating Expense: 518730.00
DME.V income_statement (quarterly, 2026-03-31) — +Total Revenue: 162998.00
DME.V balance_sheet (quarterly, 2026-03-31) — Accounts Payable: 287279.00
DME.V balance_sheet (quarterly, 2026-03-31) — Accounts Receivable: 206717.00
DME.V balance_sheet (quarterly, 2026-03-31) — Accumulated Depreciation: -11171028.00
DME.V income_statement (quarterly, 2026-03-31) — Basic Average Shares: 95771910.00
DME.V income_statement (quarterly, 2026-03-31) — Basic EPS: 0.00
DME.V cash_flow (quarterly, 2026-03-31) — Beginning Cash Position: 54070.00
DME.V cash_flow (quarterly, 2026-03-31) — Capital Expenditure: -68813.00
DME.V cash_flow (quarterly, 2026-03-31) — Capital Expenditure Reported: -68813.00
DME.V balance_sheet (quarterly, 2026-03-31) — Capital Stock: 82106004.00
DME.V balance_sheet (quarterly, 2026-03-31) — Cash And Cash Equivalents: 188030.00
DME.V balance_sheet (quarterly, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 188030.00
DME.V cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Financing Activities: 376026.00
DME.V cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Investing Activities: -35388.00
DME.V cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Operating Activities: -316831.00
DME.V cash_flow (quarterly, 2026-03-31) — Change In Account Payable: -21682.00
DME.V cash_flow (quarterly, 2026-03-31) — Change In Payable: -21682.00
DME.V cash_flow (quarterly, 2026-03-31) — Change In Payables And Accrued Expense: -21682.00
DME.V cash_flow (quarterly, 2026-03-31) — Change In Prepaid Assets: -30136.00
DME.V cash_flow (quarterly, 2026-03-31) — Change In Receivables: -16870.00
DME.V cash_flow (quarterly, 2026-03-31) — Change In Working Capital: -68688.00
DME.V cash_flow (quarterly, 2026-03-31) — Changes In Cash: 23807.00
DME.V balance_sheet (quarterly, 2026-03-31) — Common Stock: 82106004.00
DME.V balance_sheet (quarterly, 2026-03-31) — Common Stock Equity: 47595226.00
DME.V income_statement (quarterly, 2026-03-31) — Cost Of Revenue: 90417.00
DME.V balance_sheet (quarterly, 2026-03-31) — Current Assets: 737343.00
DME.V balance_sheet (quarterly, 2026-03-31) — Current Liabilities: 287279.00
DME.V cash_flow (quarterly, 2026-03-31) — Depletion: 644.00
DME.V cash_flow (quarterly, 2026-03-31) — Depreciation: 45548.00
DME.V cash_flow (quarterly, 2026-03-31) — Depreciation Amortization Depletion: 46192.00
DME.V income_statement (quarterly, 2026-03-31) — Depreciation Amortization Depletion Income Statement: 45548.00
DME.V cash_flow (quarterly, 2026-03-31) — Depreciation And Amortization: 45548.00
DME.V income_statement (quarterly, 2026-03-31) — Depreciation And Amortization In Income Statement: 45548.00
DME.V income_statement (quarterly, 2026-03-31) — Depreciation Income Statement: 45548.00
DME.V income_statement (quarterly, 2026-03-31) — Diluted Average Shares: 95771910.00
DME.V income_statement (quarterly, 2026-03-31) — Diluted EPS: 0.00
DME.V income_statement (quarterly, 2026-03-31) — Diluted NI Availto Com Stockholders: -283192.00
DME.V income_statement (quarterly, 2026-03-31) — EBIT: -446149.00
DME.V income_statement (quarterly, 2026-03-31) — EBITDA: -399957.00
DME.V cash_flow (quarterly, 2026-03-31) — Effect Of Exchange Rate Changes: 110153.00
DME.V cash_flow (quarterly, 2026-03-31) — End Cash Position: 188030.00
DME.V cash_flow (quarterly, 2026-03-31) — Financing Cash Flow: 376026.00
DME.V cash_flow (quarterly, 2026-03-31) — Free Cash Flow: -385644.00
DME.V income_statement (quarterly, 2026-03-31) — Gain On Sale Of Security: 138.00
DME.V balance_sheet (quarterly, 2026-03-31) — Gains Losses Not Affecting Retained Earnings: 3280174.00
DME.V income_statement (quarterly, 2026-03-31) — General And Administrative Expense: 241768.00
DME.V balance_sheet (quarterly, 2026-03-31) — Gross PPE: 59846526.00
DME.V income_statement (quarterly, 2026-03-31) — Gross Profit: 72581.00
DME.V balance_sheet (quarterly, 2026-03-31) — Held To Maturity Securities: 196421.00
DME.V income_statement (quarterly, 2026-03-31) — Insurance And Claims: 36975.00
DME.V income_statement (quarterly, 2026-03-31) — Interest Income: 29932.00
DME.V income_statement (quarterly, 2026-03-31) — Interest Income Non Operating: 29932.00
DME.V balance_sheet (quarterly, 2026-03-31) — Invested Capital: 47595226.00
DME.V cash_flow (quarterly, 2026-03-31) — Investing Cash Flow: -35388.00
DME.V balance_sheet (quarterly, 2026-03-31) — Investmentin Financial Assets: 196421.00
DME.V balance_sheet (quarterly, 2026-03-31) — Investments And Advances: 196421.00
DME.V balance_sheet (quarterly, 2026-03-31) — Land And Improvements: 279979.00
DME.V balance_sheet (quarterly, 2026-03-31) — Long Term Provisions: 2942102.00
DME.V cash_flow (quarterly, 2026-03-31) — Net Foreign Currency Exchange Gain Loss: -24942.00
DME.V income_statement (quarterly, 2026-03-31) — Net Income: -283192.00
DME.V income_statement (quarterly, 2026-03-31) — Net Income Common Stockholders: -283192.00
DME.V income_statement (quarterly, 2026-03-31) — Net Income Continuous Operations: -283192.00
DME.V income_statement (quarterly, 2026-03-31) — Net Income From Continuing And Discontinued Operation: -283192.00
DME.V income_statement (quarterly, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: -283192.00
DME.V cash_flow (quarterly, 2026-03-31) — Net Income From Continuing Operations: -283192.00
DME.V income_statement (quarterly, 2026-03-31) — Net Income Including Noncontrolling Interests: -283192.00
DME.V income_statement (quarterly, 2026-03-31) — Net Interest Income: 29932.00
DME.V income_statement (quarterly, 2026-03-31) — Net Non Operating Interest Income Expense: 29932.00
DME.V cash_flow (quarterly, 2026-03-31) — Net Other Investing Changes: 33425.00
DME.V balance_sheet (quarterly, 2026-03-31) — Net PPE: 48675498.00
DME.V balance_sheet (quarterly, 2026-03-31) — Net Tangible Assets: 47595226.00
DME.V balance_sheet (quarterly, 2026-03-31) — Non Current Accounts Receivable: 387375.00
DME.V income_statement (quarterly, 2026-03-31) — Normalized EBITDA: -532982.00
DME.V income_statement (quarterly, 2026-03-31) — Normalized Income: -416217.00
DME.V cash_flow (quarterly, 2026-03-31) — Operating Cash Flow: -316831.00
DME.V cash_flow (quarterly, 2026-03-31) — Operating Gains Losses: -24942.00
DME.V income_statement (quarterly, 2026-03-31) — Operating Income: -446149.00
DME.V income_statement (quarterly, 2026-03-31) — Operating Revenue: 162998.00
DME.V balance_sheet (quarterly, 2026-03-31) — Ordinary Shares Number: 96223149.00
DME.V balance_sheet (quarterly, 2026-03-31) — Other Equity Adjustments: 3280174.00
DME.V balance_sheet (quarterly, 2026-03-31) — Other Equity Interest: 17586946.00
DME.V income_statement (quarterly, 2026-03-31) — Other Gand A: 188546.00
DME.V income_statement (quarterly, 2026-03-31) — Other Income Expense: 133025.00
DME.V cash_flow (quarterly, 2026-03-31) — Other Non Cash Items: 13799.00
DME.V balance_sheet (quarterly, 2026-03-31) — Other Non Current Assets: 827970.00
DME.V income_statement (quarterly, 2026-03-31) — Other Operating Expenses: 118428.00
DME.V balance_sheet (quarterly, 2026-03-31) — Other Properties: 59566547.00
DME.V balance_sheet (quarterly, 2026-03-31) — Other Receivables: 273546.00
DME.V balance_sheet (quarterly, 2026-03-31) — Payables: 287279.00
DME.V balance_sheet (quarterly, 2026-03-31) — Payables And Accrued Expenses: 287279.00
DME.V balance_sheet (quarterly, 2026-03-31) — Prepaid Assets: 69050.00
DME.V income_statement (quarterly, 2026-03-31) — Pretax Income: -283192.00
DME.V cash_flow (quarterly, 2026-03-31) — Proceeds From Stock Option Exercised: 69283.00
DME.V balance_sheet (quarterly, 2026-03-31) — Receivables: 480263.00
DME.V income_statement (quarterly, 2026-03-31) — Reconciled Cost Of Revenue: 89773.00
DME.V income_statement (quarterly, 2026-03-31) — Reconciled Depreciation: 46192.00
DME.V income_statement (quarterly, 2026-03-31) — Restructuring And Mergern Acquisition: -132887.00
DME.V balance_sheet (quarterly, 2026-03-31) — Retained Earnings: -55377898.00
DME.V income_statement (quarterly, 2026-03-31) — Salaries And Wages: 16247.00
DME.V income_statement (quarterly, 2026-03-31) — Selling And Marketing Expense: 18801.00
DME.V income_statement (quarterly, 2026-03-31) — Selling General And Administration: 260569.00
DME.V balance_sheet (quarterly, 2026-03-31) — Share Issued: 96223149.00
DME.V income_statement (quarterly, 2026-03-31) — Special Income Charges: 132887.00
DME.V balance_sheet (quarterly, 2026-03-31) — Stockholders Equity: 47595226.00
DME.V balance_sheet (quarterly, 2026-03-31) — Tangible Book Value: 47595226.00
DME.V income_statement (quarterly, 2026-03-31) — Tax Effect Of Unusual Items: 0.00
DME.V income_statement (quarterly, 2026-03-31) — Tax Rate For Calcs: 0.00
DME.V balance_sheet (quarterly, 2026-03-31) — Total Assets: 50824607.00
DME.V balance_sheet (quarterly, 2026-03-31) — Total Capitalization: 47595226.00
DME.V balance_sheet (quarterly, 2026-03-31) — Total Equity Gross Minority Interest: 47595226.00
DME.V income_statement (quarterly, 2026-03-31) — Total Expenses: 609147.00
DME.V balance_sheet (quarterly, 2026-03-31) — Total Liabilities Net Minority Interest: 3229381.00
DME.V balance_sheet (quarterly, 2026-03-31) — Total Non Current Assets: 50087264.00
DME.V balance_sheet (quarterly, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 2942102.00
DME.V income_statement (quarterly, 2026-03-31) — Total Unusual Items: 133025.00
DME.V income_statement (quarterly, 2026-03-31) — Total Unusual Items Excluding Goodwill: 133025.00
DME.V balance_sheet (quarterly, 2026-03-31) — Working Capital: 450064.00
DMG.AX income_statement (annual, 2021-06-30) — +Operating Expense: 682011.00
DMG.AX balance_sheet (annual, 2021-06-30) — Accounts Payable: 594046.00
DMG.AX balance_sheet (annual, 2021-06-30) — Accumulated Depreciation: -1059999.00
DMG.AX income_statement (annual, 2021-06-30) — Basic Average Shares: 263530515.00
DMG.AX income_statement (annual, 2021-06-30) — Basic EPS: 0.00
DMG.AX cash_flow (annual, 2021-06-30) — Beginning Cash Position: 1237986.00
DMG.AX cash_flow (annual, 2021-06-30) — Capital Expenditure: -88249.00
DMG.AX cash_flow (annual, 2021-06-30) — Capital Expenditure Reported: -88249.00
DMG.AX balance_sheet (annual, 2021-06-30) — Capital Lease Obligations: 160114.00
DMG.AX balance_sheet (annual, 2021-06-30) — Capital Stock: 33081803.00
DMG.AX balance_sheet (annual, 2021-06-30) — Cash And Cash Equivalents: 818599.00
DMG.AX balance_sheet (annual, 2021-06-30) — Cash Cash Equivalents And Short Term Investments: 818599.00
DMG.AX balance_sheet (annual, 2021-06-30) — Cash Financial: 818599.00
DMG.AX cash_flow (annual, 2021-06-30) — Cash Flow From Continuing Investing Activities: -88249.00
DMG.AX cash_flow (annual, 2021-06-30) — Cash Flowsfromusedin Operating Activities Direct: -331138.00
DMG.AX cash_flow (annual, 2021-06-30) — Changes In Cash: -419387.00
DMG.AX cash_flow (annual, 2021-06-30) — Classesof Cash Payments: -345148.00
DMG.AX cash_flow (annual, 2021-06-30) — Classesof Cash Receiptsfrom Operating Activities: 10000.00
DMG.AX balance_sheet (annual, 2021-06-30) — Common Stock: 33081803.00
DMG.AX balance_sheet (annual, 2021-06-30) — Common Stock Equity: -34102.00
DMG.AX balance_sheet (annual, 2021-06-30) — Current Assets: 887245.00
DMG.AX balance_sheet (annual, 2021-06-30) — Current Capital Lease Obligation: 105722.00
DMG.AX balance_sheet (annual, 2021-06-30) — Current Debt: 3125.00
DMG.AX balance_sheet (annual, 2021-06-30) — Current Debt And Capital Lease Obligation: 108847.00
DMG.AX balance_sheet (annual, 2021-06-30) — Current Liabilities: 1007437.00
DMG.AX income_statement (annual, 2021-06-30) — Depreciation Amortization Depletion Income Statement: 92062.00
DMG.AX income_statement (annual, 2021-06-30) — Depreciation And Amortization In Income Statement: 92062.00
DMG.AX income_statement (annual, 2021-06-30) — Depreciation Income Statement: 92062.00
DMG.AX income_statement (annual, 2021-06-30) — Diluted Average Shares: 263530515.00
DMG.AX income_statement (annual, 2021-06-30) — Diluted EPS: 0.00
DMG.AX income_statement (annual, 2021-06-30) — EBIT: -673000.00
DMG.AX income_statement (annual, 2021-06-30) — EBITDA: -580938.00
DMG.AX cash_flow (annual, 2021-06-30) — End Cash Position: 818599.00
DMG.AX balance_sheet (annual, 2021-06-30) — Foreign Currency Translation Adjustments: 1040.00
DMG.AX cash_flow (annual, 2021-06-30) — Free Cash Flow: -419387.00
DMG.AX balance_sheet (annual, 2021-06-30) — Gains Losses Not Affecting Retained Earnings: 1040.00
DMG.AX income_statement (annual, 2021-06-30) — General And Administrative Expense: 339838.00
DMG.AX balance_sheet (annual, 2021-06-30) — Gross PPE: 1200481.00
DMG.AX income_statement (annual, 2021-06-30) — Interest Expense: 9191.00
DMG.AX income_statement (annual, 2021-06-30) — Interest Expense Non Operating: 9191.00
DMG.AX income_statement (annual, 2021-06-30) — Interest Income: 4011.00
DMG.AX income_statement (annual, 2021-06-30) — Interest Income Non Operating: 4011.00
DMG.AX cash_flow (annual, 2021-06-30) — Interest Received Direct: 4010.00
DMG.AX balance_sheet (annual, 2021-06-30) — Invested Capital: -30977.00
DMG.AX cash_flow (annual, 2021-06-30) — Investing Cash Flow: -88249.00
DMG.AX balance_sheet (annual, 2021-06-30) — Leases: 211499.00
DMG.AX balance_sheet (annual, 2021-06-30) — Long Term Capital Lease Obligation: 54392.00
DMG.AX balance_sheet (annual, 2021-06-30) — Long Term Debt And Capital Lease Obligation: 54392.00
DMG.AX balance_sheet (annual, 2021-06-30) — Machinery Furniture Equipment: 54213.00
DMG.AX income_statement (annual, 2021-06-30) — Net Income: -682191.00
DMG.AX income_statement (annual, 2021-06-30) — Net Income Common Stockholders: -682191.00
DMG.AX income_statement (annual, 2021-06-30) — Net Income Continuous Operations: -682191.00
DMG.AX income_statement (annual, 2021-06-30) — Net Income From Continuing And Discontinued Operation: -682191.00
DMG.AX income_statement (annual, 2021-06-30) — Net Income From Continuing Operation Net Minority Interest: -682191.00
DMG.AX income_statement (annual, 2021-06-30) — Net Income Including Noncontrolling Interests: -682191.00
DMG.AX income_statement (annual, 2021-06-30) — Net Interest Income: -5180.00
DMG.AX income_statement (annual, 2021-06-30) — Net Non Operating Interest Income Expense: -5180.00
DMG.AX balance_sheet (annual, 2021-06-30) — Net PPE: 140482.00
DMG.AX balance_sheet (annual, 2021-06-30) — Net Tangible Assets: -34102.00
DMG.AX income_statement (annual, 2021-06-30) — Normalized EBITDA: -580938.00
DMG.AX income_statement (annual, 2021-06-30) — Normalized Income: -682191.00
DMG.AX income_statement (annual, 2021-06-30) — Operating Income: -682011.00
DMG.AX balance_sheet (annual, 2021-06-30) — Ordinary Shares Number: 263530515.00
DMG.AX cash_flow (annual, 2021-06-30) — Other Cash Receiptsfrom Operating Activities: 10000.00
DMG.AX balance_sheet (annual, 2021-06-30) — Other Current Borrowings: 3125.00
DMG.AX income_statement (annual, 2021-06-30) — Other Income Expense: 5000.00
DMG.AX income_statement (annual, 2021-06-30) — Other Non Operating Income Expenses: 5000.00
DMG.AX income_statement (annual, 2021-06-30) — Other Operating Expenses: 250111.00
DMG.AX balance_sheet (annual, 2021-06-30) — Other Payable: 304544.00
DMG.AX balance_sheet (annual, 2021-06-30) — Other Properties: 934769.00
DMG.AX balance_sheet (annual, 2021-06-30) — Other Receivables: 59323.00
DMG.AX balance_sheet (annual, 2021-06-30) — Payables: 898590.00
DMG.AX balance_sheet (annual, 2021-06-30) — Payables And Accrued Expenses: 898590.00
DMG.AX cash_flow (annual, 2021-06-30) — Paymentsto Suppliersfor Goodsand Services: -345148.00
DMG.AX balance_sheet (annual, 2021-06-30) — Prepaid Assets: 9323.00
DMG.AX income_statement (annual, 2021-06-30) — Pretax Income: -682191.00
DMG.AX balance_sheet (annual, 2021-06-30) — Receivables: 59323.00
DMG.AX income_statement (annual, 2021-06-30) — Reconciled Depreciation: 92062.00
DMG.AX income_statement (annual, 2021-06-30) — Rent And Landing Fees: 1173.00
DMG.AX balance_sheet (annual, 2021-06-30) — Retained Earnings: -33116945.00
DMG.AX income_statement (annual, 2021-06-30) — Salaries And Wages: 338665.00
DMG.AX income_statement (annual, 2021-06-30) — Selling General And Administration: 339838.00
DMG.AX balance_sheet (annual, 2021-06-30) — Share Issued: 263530515.00
DMG.AX balance_sheet (annual, 2021-06-30) — Stockholders Equity: -34102.00
DMG.AX balance_sheet (annual, 2021-06-30) — Tangible Book Value: -34102.00
DMG.AX income_statement (annual, 2021-06-30) — Tax Effect Of Unusual Items: 0.00
DMG.AX income_statement (annual, 2021-06-30) — Tax Provision: 0.00
DMG.AX income_statement (annual, 2021-06-30) — Tax Rate For Calcs: 0.00
DMG.AX balance_sheet (annual, 2021-06-30) — Total Assets: 1027727.00
DMG.AX balance_sheet (annual, 2021-06-30) — Total Capitalization: -34102.00
DMG.AX balance_sheet (annual, 2021-06-30) — Total Debt: 163239.00
DMG.AX balance_sheet (annual, 2021-06-30) — Total Equity Gross Minority Interest: -34102.00
DMG.AX balance_sheet (annual, 2021-06-30) — Total Liabilities Net Minority Interest: 1061829.00
DMG.AX balance_sheet (annual, 2021-06-30) — Total Non Current Assets: 140482.00
DMG.AX balance_sheet (annual, 2021-06-30) — Total Non Current Liabilities Net Minority Interest: 54392.00
DMG.AX balance_sheet (annual, 2021-06-30) — Working Capital: -120192.00
DMG.AX income_statement (annual, 2022-06-30) — +Operating Expense: 718613.00
DMG.AX balance_sheet (annual, 2022-06-30) — Accounts Payable: 797035.00
DMG.AX balance_sheet (annual, 2022-06-30) — Accumulated Depreciation: -952277.00
DMG.AX income_statement (annual, 2022-06-30) — Basic Average Shares: 263530515.00
DMG.AX income_statement (annual, 2022-06-30) — Basic EPS: 0.00
DMG.AX cash_flow (annual, 2022-06-30) — Beginning Cash Position: 818599.00
DMG.AX cash_flow (annual, 2022-06-30) — Capital Expenditure: -331284.00
DMG.AX cash_flow (annual, 2022-06-30) — Capital Expenditure Reported: -331284.00
DMG.AX balance_sheet (annual, 2022-06-30) — Capital Lease Obligations: 17801.00
DMG.AX balance_sheet (annual, 2022-06-30) — Capital Stock: 33081803.00
DMG.AX balance_sheet (annual, 2022-06-30) — Cash And Cash Equivalents: 1613198.00
DMG.AX balance_sheet (annual, 2022-06-30) — Cash Cash Equivalents And Short Term Investments: 1613198.00
DMG.AX balance_sheet (annual, 2022-06-30) — Cash Financial: 1613198.00
DMG.AX cash_flow (annual, 2022-06-30) — Cash Flow From Continuing Financing Activities: 1252985.00
DMG.AX cash_flow (annual, 2022-06-30) — Cash Flow From Continuing Investing Activities: -331284.00
DMG.AX cash_flow (annual, 2022-06-30) — Cash Flowsfromusedin Operating Activities Direct: -127102.00
DMG.AX cash_flow (annual, 2022-06-30) — Changes In Cash: 794599.00
DMG.AX cash_flow (annual, 2022-06-30) — Classesof Cash Payments: -131077.00
DMG.AX balance_sheet (annual, 2022-06-30) — Common Stock: 33081803.00
DMG.AX balance_sheet (annual, 2022-06-30) — Common Stock Equity: -687539.00
DMG.AX cash_flow (annual, 2022-06-30) — Common Stock Issuance: 1252985.00
DMG.AX balance_sheet (annual, 2022-06-30) — Current Assets: 1650890.00
DMG.AX balance_sheet (annual, 2022-06-30) — Current Capital Lease Obligation: 17801.00
DMG.AX balance_sheet (annual, 2022-06-30) — Current Debt And Capital Lease Obligation: 17801.00
DMG.AX balance_sheet (annual, 2022-06-30) — Current Liabilities: 2715556.00
DMG.AX income_statement (annual, 2022-06-30) — Depreciation Amortization Depletion Income Statement: 86924.00
DMG.AX income_statement (annual, 2022-06-30) — Depreciation And Amortization In Income Statement: 86924.00
DMG.AX income_statement (annual, 2022-06-30) — Depreciation Income Statement: 86924.00
DMG.AX income_statement (annual, 2022-06-30) — Diluted Average Shares: 263530515.00
DMG.AX income_statement (annual, 2022-06-30) — Diluted EPS: 0.00
DMG.AX income_statement (annual, 2022-06-30) — EBIT: -651628.00
DMG.AX income_statement (annual, 2022-06-30) — EBITDA: -564704.00
DMG.AX cash_flow (annual, 2022-06-30) — End Cash Position: 1613198.00
DMG.AX cash_flow (annual, 2022-06-30) — Financing Cash Flow: 1252985.00
DMG.AX balance_sheet (annual, 2022-06-30) — Foreign Currency Translation Adjustments: 1040.00
DMG.AX cash_flow (annual, 2022-06-30) — Free Cash Flow: -458386.00
DMG.AX balance_sheet (annual, 2022-06-30) — Gains Losses Not Affecting Retained Earnings: 1040.00
DMG.AX income_statement (annual, 2022-06-30) — General And Administrative Expense: 272385.00
DMG.AX balance_sheet (annual, 2022-06-30) — Gross PPE: 1663224.00
DMG.AX income_statement (annual, 2022-06-30) — Interest Expense: 1809.00
DMG.AX income_statement (annual, 2022-06-30) — Interest Expense Non Operating: 1809.00
DMG.AX income_statement (annual, 2022-06-30) — Interest Income: 3975.00
DMG.AX income_statement (annual, 2022-06-30) — Interest Income Non Operating: 3975.00
DMG.AX cash_flow (annual, 2022-06-30) — Interest Received Direct: 3975.00
DMG.AX balance_sheet (annual, 2022-06-30) — Invested Capital: -687539.00
DMG.AX cash_flow (annual, 2022-06-30) — Investing Cash Flow: -331284.00
DMG.AX cash_flow (annual, 2022-06-30) — Issuance Of Capital Stock: 1252985.00
DMG.AX balance_sheet (annual, 2022-06-30) — Machinery Furniture Equipment: 70827.00
DMG.AX cash_flow (annual, 2022-06-30) — Net Common Stock Issuance: 1252985.00
DMG.AX income_statement (annual, 2022-06-30) — Net Income: -653437.00
DMG.AX income_statement (annual, 2022-06-30) — Net Income Common Stockholders: -653437.00
DMG.AX income_statement (annual, 2022-06-30) — Net Income Continuous Operations: -653437.00
DMG.AX income_statement (annual, 2022-06-30) — Net Income From Continuing And Discontinued Operation: -653437.00
DMG.AX income_statement (annual, 2022-06-30) — Net Income From Continuing Operation Net Minority Interest: -653437.00
DMG.AX income_statement (annual, 2022-06-30) — Net Income Including Noncontrolling Interests: -653437.00
DMG.AX income_statement (annual, 2022-06-30) — Net Interest Income: 2166.00